Ph.D. Supervisor, Chief Physician, and Deputy Director of the Department of Endocrinology at the First Affiliated Hospital of the University of Science and Technology of China (USTC). Ph.D. Supervisor at USTC and Postdoctoral Mentor at the First Affiliated Hospital of USTC. Youth Committee Member of the Chinese Society of Osteoporosis and Bone Mineral Research, Standing Committee Member of the Endocrinology and Metabolism Branch of the Anhui Medical Association, and Member of the Diabetes Branch of the Anhui Medical Association. Former Visiting Scholar at Rutgers University, USA.
Education and Work Experience
- 2002: Bachelor of Medicine, Anhui Medical University
- 2007: Ph.D. in Science, University of Science and Technology of China
- 2007-Present: First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Academic Achievements and Impact
Dr. Wang has long been dedicated to the study of the regulation and function of acid-sensing ion channels in the central nervous system, as well as the interaction between diabetes and bone metabolic diseases. He has published over 10 papers as the first author or corresponding author in international and domestic academic journals such as JBC, J Neuro Res, and Chinese Journal of Diabetes.
Ongoing Projects (Principal Investigator Only)
1. Project Name: Regulation of HPA Axis Activity by Hypothalamic Acid-Sensing Ion Channel 1a and Its Impact on Blood Glucose in Diabetic Conditions
- Source: National Natural Science Foundation of China General Project
- Funding: 550,000 RMB
- Duration: 2021-01 to 2023-12
2. Project Name: Study on the Impact of Hypothalamic ASIC1a Regulation of HPA Axis Activity on Blood Glucose
- Source: Open Project of the Key Laboratory of the Chinese Academy of Sciences
- Funding: 50,000 RMB
- Duration: 2019-08 to 2022-07
Main Research Areas (Graduate Programs)
Clinical Medicine (Internal Medicine), Biology:
1. The role of receptor ion channels in the pathogenesis and intervention of endocrine metabolic diseases
2. Clinical and basic research on diabetes combined with bone metabolic diseases
3. Application of artificial intelligence in the management of chronic endocrine metabolic diseases
Representative Papers (Last Five Years)
1、Zhou W, Ye SD, Wang W*. miR-217 alleviates high-glucose-induced vascular smooth muscle cell dysfunction via regulating ROCK1. Journal of Biochemical and Molecular Toxicology. 2021 Mar;35(3):e22668.
2、Wang W*, Hu G, Yuan B, Ye S, Chen C, Cui Y, Zhang X, Qian L*. Prior-knowledge-driven local causal structure learning and its application on causal discovery between type 2 diabetes and bone mineral density. IEEE Access. 2020, 8：108798-108810.
3、Zhou W, Ye SD, Luo R, Wu LM, Wang W*. Inhibition of acid-sensing ion channels reduces the hypothalamus-pituitary-adrenal axis activity and ameliorates depression-like behavior in rats. RSC Advances. 2019, 9:8707-8713.
4、Wang W*, Ye SD*, Qian L, Xing Y, Ren A, Chen C, Li S, Xu J, Liu Q, Dong L, Xiao C, Zhou W. Elevated serum lipocalin 2 levels are associated with indexes of both glucose and bone metabolism in type 2 diabetes mellitus. Endokrynologia Polska. 2018, 69 (3): 276–282.
5、Wang W*, Ye SD, Qian L, Xing X. Sex-specific association of serum 25-hydroxyvitamin D3 with insulin resistance in Chinese Han patients with newly diagnosed type 2 diabetes mellitus. Journal of Nutritional Science and Vitaminology. 2018, 64(3):173-178.
Contact Information
E-mail: hfww2001@ustc.edu.cn
Phone: 0551-62283346